Literature DB >> 11502523

Isolation of rat dihydrofolate reductase gene and characterization of recombinant enzyme.

Y Wang1, J A Bruenn, S F Queener, V Cody.   

Abstract

While assays of many antifolate inhibitors for dihydrofolate reductase (DHFR) have been performed using rat DHFR as a target, neither the sequence nor the structure of rat DHFR is known. Here, we report the isolation of the rat DHFR gene through screening of a rat liver cDNA library. The rat liver DHFR gene has an open reading frame of 561 bp encoding a protein of 187 amino acids. Comparisons of the rat enzyme with those from other species indicate a high level of conservation at the primary sequence level and more so for the amino acid residues comprising the active site of the enzyme. Expression of the rat DHFR gene in bacteria produced a recombinant protein with high enzymatic activity. The recombinant protein also paralleled the human enzyme with respect to the inhibition by most of the antifolates tested with PT652 and PT653 showing a reversal in their patterns. Our results indicated that rat DHFR can be used as a model to study antifolate compounds as potential drug candidates. However, variations between rat and human DHFR enzymes, coupled with unique features in the inhibitors, could lead to the observed differences in enzyme sensitivity and selectivity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11502523      PMCID: PMC90686          DOI: 10.1128/AAC.45.9.2517-2523.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  47 in total

1.  Nonclassical 2,4-diamino-5-aryl-6-ethylpyrimidine antifolates: activity as inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.

Authors:  C Robson; M A Meek; J D Grunwaldt; P A Lambert; S F Queener; D Schmidt; R J Griffin
Journal:  J Med Chem       Date:  1997-09-12       Impact factor: 7.446

2.  Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs.

Authors:  R Li; R Sirawaraporn; P Chitnumsub; W Sirawaraporn; J Wooden; F Athappilly; S Turley; W G Hol
Journal:  J Mol Biol       Date:  2000-01-14       Impact factor: 5.469

3.  Structural studies on bioactive compounds. 30. Crystal structure and molecular modeling studies on the Pneumocystis carinii dihydrofolate reductase cofactor complex with TAB, a highly selective antifolate.

Authors:  V Cody; D Chan; N Galitsky; D Rak; J R Luft; W Pangborn; S F Queener; C A Laughton; M F Stevens
Journal:  Biochemistry       Date:  2000-04-04       Impact factor: 3.162

Review 4.  New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii.

Authors:  S F Queener
Journal:  J Med Chem       Date:  1995-11-24       Impact factor: 7.446

5.  Role of lysine-54 in determining cofactor specificity and binding in human dihydrofolate reductase.

Authors:  S Huang; R Appleman; X H Tan; P D Thompson; R L Blakley; R P Sheridan; R Venkataraghavan; J H Freisheim
Journal:  Biochemistry       Date:  1990-09-04       Impact factor: 3.162

6.  Comparison of ternary complexes of Pneumocystis carinii and wild-type human dihydrofolate reductase with coenzyme NADPH and a novel classical antitumor furo[2,3-d]pyrimidine antifolate.

Authors:  V Cody; N Galitsky; J R Luft; W Pangborn; A Gangjee; R Devraj; S F Queener; R L Blakley
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1997-11-01

7.  Pneumocystis carinii dihydrofolate reductase used to screen potential antipneumocystis drugs.

Authors:  M C Broughton; S F Queener
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

8.  Purification and characterization of dihydrofolate reductase from Walker 256 carcinosarcoma.

Authors:  S J Johnson; S V Gupta; K J Stevenson; J H Freisheim
Journal:  Can J Biochem       Date:  1982-12

9.  Crystal structure determination at 2.3 A of recombinant human dihydrofolate reductase ternary complex with NADPH and methotrexate-gamma-tetrazole.

Authors:  V Cody; J R Luft; E Ciszak; T I Kalman; J H Freisheim
Journal:  Anticancer Drug Des       Date:  1992-12

10.  Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations.

Authors:  J R Piper; C A Johnson; C A Krauth; R L Carter; C A Hosmer; S F Queener; S E Borotz; E R Pfefferkorn
Journal:  J Med Chem       Date:  1996-03-15       Impact factor: 7.446

View more
  3 in total

1.  The former annotated human pseudogene dihydrofolate reductase-like 1 (DHFRL1) is expressed and functional.

Authors:  Gráinne McEntee; Stefano Minguzzi; Kirsty O'Brien; Nadia Ben Larbi; Christine Loscher; Ciarán O'Fágáin; Anne Parle-McDermott
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-26       Impact factor: 11.205

2.  Interpretable correlation descriptors for quantitative structure-activity relationships.

Authors:  Benson M Spowage; Craig L Bruce; Jonathan D Hirst
Journal:  J Cheminform       Date:  2009-12-24       Impact factor: 5.514

3.  Cloning, expression, and characterization of Babesia gibsoni dihydrofolate reductase-thymidylate synthase: inhibitory effect of antifolates on its catalytic activity and parasite proliferation.

Authors:  Gabriel O Aboge; Honglin Jia; Mohamad A Terkawi; Youn-Kyoung Goo; Yoshifumi Nishikawa; Fujiko Sunaga; Kuzuhiko Namikawa; Naotoshi Tsuji; Ikuo Igarashi; Hiroshi Suzuki; Kozo Fujisaki; Xuenan Xuan
Journal:  Antimicrob Agents Chemother       Date:  2008-09-15       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.